The concept of the natural history or spontaneous evolution of vascular diseases varies from one side of the globe to the other. Specialist opinion differs on radiologically identical disease. Arterial aneurysms in the posterior fossa, for example, seem to signify different diseases (or identical conditions in different degrees) in Asia and Europe. Even if the sign of a dysfunction may be displayed at a given time in the same image, individual biology differ in these two areas of our planet.
The subsequent stage and the next sign of the disease may be completely different. Somewhat as if the same word or sound in two very different languages had two very different meanings. Likewise, therapeutic decisions taken by two teams working in different environments may be very different, even contradictory for apparently the same lesions. While good faith like the good will of the individuals involved is not at issue, medical approaches and technical choices have nowadays become a reflection of the industrial interests (or pressures) at stake and the administrative regulations in force (product certification, financing working budgets ... ).
The procedures authorized by the FDA in the USA, those in force in Japan, budget restrictions in Europe, south-east Asia or Africa
"Scientific Truth Does Not Exist"
A. Einstein and the total lack of means in yet other countries, and the fact that the price of a catheter is five times higher from one country to the next, all hinder the universal implementation of therapeutic techniques. As a result, evidence for clinical effectiveness will only be a secondary consideration in the adoption of a therapy. Today, the indication for therapeutic action and the technical challenge take precedence over the clinical aim. Each forum upholds the use of one or or the other method with enthusiasm -as if one could talk about a painting solely in terms of brush strokes. The reactions to incidental aneurysms, ischaemic cerebral vascular accidents, cerebral arteriovenous malformations and giant aneurysms are as much a clinical excuse to tackle problems of "tools", an excuse in the sense that these debates are less about the patients than the doctors with their individual fears, habits and privileges.
What then is the point of an international literature? There is no real desire to have an objective exchange, but to circulate consumer information on everything, without this upsetting readers' opinions, their customs or their lives: what keeps the literature alive is no longer the author but the reader.
Current bibliographies are often mere complacent inventories, free of contradiction and comfortable for the authors, the omissions betraying the cultural origin of one or other. Scientific journals of this ilk risk becoming ordinary (albeit well-read) magazines. Finally the interdependence between doctor and industry and doctor and health authority yearned for by all concerned has served to remove modern doctors one step further away from the Hippocratic oath and its code of medical ethics.
Medicine in general and interventional neuroradiology in particular are in the process of becoming the pawns of professional medicine (doctors), technology (industry) and public health (management). As a result, the quality of life or survival of patients become indicators for a technical follow-up rather than a primary objective.
The dural arteriovenous shunts described in this issue are a perfect example: a case for the P. Lasjaunias use of cyano-acrylate particles to surgery inserting intravenous coils; two medically similar situations treated differently for cultural rather than scientific reasons.
Although the end undoubtedly justifies the means in a given place, is it normal to spend ten times more doing something which can be done as well for ten times less? Of course, these less expensive techniques require slightly longer training and slightly more expertise, and longer more specific training is not recommended.
The difficulties in obtaining grants for high level clinical training abroad demonstrate our (western) world's desire to support research sojourns (theses or doctorates) which will give rise to patents.
The spin-offs, profits and new markets which ensue are only indirectly linked to improvements in patient care.
